Detalles de la búsqueda
1.
Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases.
J Med Chem;
63(11): 5697-5722, 2020 06 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32073845
2.
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.
J Med Chem;
62(9): 4656-4668, 2019 05 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30995036
3.
The Discovery of ( S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1 H-inden-4-yl)pyridin-2-yl)-5-methyl-1 H-pyrazole-4-carboxylic Acid, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma.
J Med Chem;
61(6): 2552-2570, 2018 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-29498522
4.
The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.
J Med Chem;
61(4): 1622-1635, 2018 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-29400470
5.
Epithelial Na+ channel inhibitors for the treatment of cystic fibrosis.
Pharm Pat Anal;
6(4): 179-188, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28696180
6.
Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration.
J Med Chem;
58(23): 9273-86, 2015 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26568411
Resultados
1 -
6
de 6
1
Próxima >
>>